Amneal Pharmaceuticals Raises FY2025 Adj EPS Guidance from $0.65-$0.70 to $0.70-$0.75 vs $0.70 Est; Affirms FY2025 Sales Guidance of $3.000B-$3.100B vs $3.012B Est

Author: Benzinga Newsdesk | August 05, 2025 05:02am

Raising Full Year 2025 Financial Guidance

The Company is raising its previously provided full year 2025 guidance.

Updated Guidance	Prior Guidance
Net revenue	$3.0 billion - $3.1 billion	$3.0 billion - $3.1 billion
Adjusted EBITDA (1)	$665 million - $685 million	$650 million - $675 million
Adjusted diluted EPS (2)	$0.70 - $0.75	$0.65 - $0.70
Operating cash flow	$275 million - $305 million	$255 million - $285 million
Operating cash flow, excluding discrete items (3)	$300 million - $330 million	$280 million - $310 million
Capital expenditures (4)	Approximately $100 million	Approximately $100 million

Posted In: AMRX